CAR-T therapy for solid tumors / Alaunos Therap - LARVOL DELTA

"The official agenda for CAR-TCR Europe 2021 is now live - https://t.co/vUr8s7Z9WH #cartcr #tcell featuring @KitePharma @ziopharm @MedigeneAG @TakedaOncology @bmsnews @Novartis @Adaptimmune @JanssenEMEA @ziopharm" (@CAR_TCell)

Oncology

Effect of Longan polysaccharides on proliferation and phenotype maintenance in rabbit articular chondrocytes in vitro. (PubMed) - "All the evidences revealed that LP may replace the growth factors to be applied in ACI therapy. This study might provide a basis for development of a novel agent in the treatment of articular cartilage defect."

Journal • Biosimilar

Ziopharm Oncology reports financial results for fourth quarter and full year 2019 (GlobeNewswire, ZIOPHARM Oncology Inc) - “The Company also expects partners at Eden BioCell to file an IND for an autologous RPM CD19 trial this year in Taiwan…Anticipated Milestones for the First Half of 2020 - Sleeping Beauty Cell Therapy Programs: Patient dosing in the NCI-led phase 2 TCR-T trial targeting solid tumors. Initiation of the CD19-specific CAR-T RPM phase 1 trial with membrane bound IL-15 at MD Anderson; Controlled IL-12 Gene Therapy Program Complete enrollment and initial data readout for phase 2 combination trial with Libtayo®. Interim data readout of phase 1 combination trial with OPDIVO®. Interim data readout from phase 1 monotherapy trial in expanded cohort.”

Enrollment status • New P1 trial • Non-US regulatory • P1 data • P2 data

Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-Generated NY-ESO-1-Specific TCR-T Cells Co-Expressing Membrane-Bound IL-15 Yields Anti-Tumor Responses (ASH 2019) - "Notwithstanding the successes for some hematological malignancies, CAR-T targets a limited number of cell-surface antigens that curtails their appeal for solid tumors...Though engraftment of TCR+ T cells was not significantly different between the two groups, the RPM TCR-mbIL15 T cell-treated mice exhibited increased frequency of CD27+TCR+ T cells (p = 0.035, n = 6-7, Mann Whitney test), a phenotype that is correlated with improved therapeutic responses in human subjects. The RPM technology can thus be adapted to co-express TCR with mbIL15 (and HER1t), which can now be scaled to provide a cost-effective approach to manufacturing a multitude of TCR-T products from a library of TCRs with the necessary complexity to manage the range of specificities and HLA restrictions to treat multiple patients."

IO Biomarker • CD27 • IL15

Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T (GlobeNewswire, ZIOPHARM Oncology Inc) - "Ziopharm Oncology, Inc...announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application (IND) for a phase 1 clinical trial to evaluate CD19-specific CAR-T, produced using a process termed rapid personalized manufacture (RPM), as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas....This study will be conducted at The University of Texas MD Anderson Cancer Center under an investigator-initiated trial expected to begin later this year."

Clinical • New trial • Regulatory

"Will you be discussing emerging CAR T gene therapies which could revolutionise the whole sector? @ziopharm @Precigen and the partnership between @SangamoTx @GileadSciences come to mind." (@Biotech2050)

Licensing / partnership

Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update (GlobeNewswire, ZIOPHARM Oncology Inc) - "Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019; Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019; Eden BioCell to advance third-generation Sleeping Beauty CAR-T for Greater China; Third cohort enrolling patients in Controlled IL-12 combination trial with OPDIVO® for recurrent glioblastoma (rGBM); Phase 2 trial of Controlled IL-12 in combination with Regeneron’s Libtayo® for patients with rGBM expected to open 2Q2019… Ziopharm is enrolling pediatric patients in its Phase 1 trial of Ad-RTS-hIL-12 with veledimex for the treatment of brain tumors at multiple U.S. sites."

Clinical • Trial status

"Who wants to untangle this mess between ziopharm, intrexon, precigen, MDACC, and @Merck? https://t.co/8QhAYN8xRo #CARTcells" (@sesiegler)

CAR T-Cell Therapy